PubMed-attributed venue

The Lancet. Oncology

4 selected PubMed bibliographic records attributed to The Lancet. Oncology. Venue attribution is reproduced from PubMed and does not imply endorsement, editorial affiliation, article quality, or scientific validity.

Bibliographic records

4 selected records.

Peptide profiles

2 connected profiles.

Publication years

3 attributed years.

Attributed bibliography

Selected records

All literature facets →

Carfilzomib · 2021 11 11

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.

Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Open attributed record →